CDMO Kaituo Biotech in the field of nucleic acid technology completes tens of millions of US dollars in Series A financing

With the advent of the era of global medical innovation, the biopharmaceutical field is experiencing the baptism of new technologies, which is expected to bring dawn to genetic diseases and rare diseases that lack effective treatments.

On April 25, CATUG Biotechnology announced the completion of tens of millions of US dollars in Series A financing (hereinafter referred to as "CATUG Biotechnology").

Kaituo Bio is an innovative technology company focusing on the development and application of new biopharmaceutical technologies.

The core team of Kaituo Biotechnology comes from top international and domestic biotechnology companies and well-known domestic and foreign universities and scientific research institutions, and has rich industrial technology and management experience in the field of gene therapy and nucleic acid therapy

Dr.

Dr.

Mr.

Zhao Fu, CEO and founding partner of Huaxin Investment, said:

The CGT field, including gene therapy, mRNA and cell therapy, is the most promising major innovation field in the biopharmaceutical industry.